The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint
Our findings position anti-DCDC2 autoantibody as a promising diagnostic biomarker for ICC, associated with poor prognostic outcomes, and elucidate its critical role in tumor growth and immune evasion through its interaction with ENO1.
Authors
- Zewei Cheng
- Wentao Sun
- Wenze Wan (ORCID: https://orcid.org/0000-0002-2147-1202)
- Houbao Liu (ORCID: https://orcid.org/0000-0003-0608-6522)
- Jiwei Zhang (ORCID: https://orcid.org/0000-0001-8912-5069)
- Yuan Li (ORCID: https://orcid.org/0000-0002-8945-170X)
- Fen Ma (ORCID: https://orcid.org/0000-0001-8297-7605)
- Sheng Shen (ORCID: https://orcid.org/0000-0002-1913-2666)
Institutions
- Fudan University (CN)
- Wuhan University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1186/s13046-025-03436-1
- Citations
- 3
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality